NOW AVAILABLE: For the Hemophilia Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for 2016.

The hemophilia market expanded over 2016 with the commercial launches of Bayer’s Kovaltry, Idelvion and Afstyla by CSL Behring, and Octapharma’s announcement of Nuwiq’s availability, all of which contributed to the 30% increase in promotional volume received. Communicating directly with patients was a priority across the majority of brands, as approximately 36% more materials targeting consumers were noted than those HCP-directed. Many of these DTC pieces featured information on patient support initiatives, such as Bayer’s Access Solutions, HeroPath and Team Novo8 from Novo Nordisk, Adynovate’s Freedom of Choice and True Identity programs, and Shire’s introduction of the Hematology Support Center after its merger with Baxalta. Invitations to events associated with the annual NHF meeting in Orlando were also widely distributed, and multiple patient apps were made available, including those offering treatment support as well as assistance to patients taking part in a study. New and familiar campaigns were also featured, often alongside messages promoting the products’ efficacy and convenience. Headlines were often utilized for greatest impact to emphasize companies’ experience and commitment to the hemophilia community. Additional insights into marketing strategies and channel utilization are available with a subscription.

2016 Hemophilia

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at

Ex-US Markets: Robin Cefalo at